NASDAQ · Biotechnology

NCEL (NCEL) Stock

$3.60 -4.13% NASDAQ: NCEL Healthcare

Valuation

MetricValue
Price$3.60
Market Cap$1.62M
P/E Ratio-0.13
P/B Ratio1.49
P/S Ratio0.00
EPS (TTM)$-26.30
52-Week High$30.80
52-Week Low$1.83
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-200.00%
ROA-25.66%
ROCE-400.00%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.00
Current Ratio2.00

Annual Financials (USD)

Metric20202021202220232024
Revenue$0$0$0$0$0
Operating Profit$-2.0M$-12.0M$-15.0M$-12.0M$-4.0M
Net Profit$-3.0M$-12.0M$-16.0M$-12.0M$-2.0M
EPS$-5.90$-8.10$-8.40$-3.20$-26.30
Op Margin—————

Balance Sheet (USD)

Metric20202021202220232024
Total Assets$1.0M$6.0M$9.0M$2.0M$2.0M
Total Liabilities$10.0M$5.0M$6.0M$11.0M$1.0M
Cash$0$5.0M$9.0M$1.0M$2.0M
Borrowings$2.0M$0$0$2.0M$0

Latest News

NewcelX Granted Patent in Brazil for NCEL-101 in Type 1 Diabetes, Expanding Global IP Portfolio GlobeNewswire · Jul 15, 2026 NewcelX Appoints World-Renowned Diabetes Cure-Focused Pioneer, Dr. Camillo Ricordi, to Scientific Advisory Board GlobeNewswire · Jul 8, 2026 NewcelX Announces Successful FDA Pre-IND Meeting with Clear Path Forward for NCEL-101 Toward Starting Clinical Trials for Type 1 Diabetes GlobeNewswire · Jul 1, 2026 NewcelX Publishes Peer-Reviewed Study Demonstrating Broad Therapeutic Potential of its Stem Cell Technology Platform GlobeNewswire · Jun 15, 2026 NewCelX Ltd. Submits Pre-IND Package to the FDA for NCEL-101 for the Treatment of Type 1 Diabetes GlobeNewswire · May 27, 2026

Cash Flow (USD)

Metric20202021202220232024
Operating Cash Flow$-1.0M$-15.0M$-14.0M$-10.0M$-4.0M
Investing Cash Flow$0$0$-4.0M$0$0
Financing Cash Flow$-1.0M$8.0M$7.0M$0$0
Net Cash Flow$0$5.0M$4.0M$-8.0M$1.0M
Free Cash Flow$-1.0M$-15.0M$-14.0M$-10.0M$-4.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA—
FCF Yield-306.60%
Quick Ratio2.77
Interest Coverage—
Return 1Y-82.12%
Return 3Y-98.91%
Return 5Y-99.68%

Ownership

Insiders Held68.06%
Institutions Held1.14%
Institutions Float Held3.57%
Institutional HolderSharesReport Date
UBS Group AG6842026-03-31
Caitong International Asset Management Co., Ltd12026-03-31
Tower Research Capital LLC (TRC)1472026-03-31
Corecap Advisors, LLC32026-06-30

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
BACKIMAC Holdings, Inc. $0.02 +0.00% -0.01 $79484 0.00%
BCTXWBriaCell Therapeutics Corp. $0.00 — 0.00 $1695 0.00%
CELUCelularity Inc. $0.75 +0.13% -0.20 $21.74M 0.00%
CEROCERo Therapeutics Holdings, Inc. $0.01 -7.69% 0.00 $14464 0.00%
KTTA $0.45 -2.17% -0.25 $3.35M 0.00%

About NCEL

NCEL is led by CEO Ronen Twito, employs 11 people, headquartered in CH, publicly traded since 2025.

NCEL stock trades at $3.60 with a market capitalization of $1.62M. The stock is valued at a price-to-earnings (P/E) ratio of -0.13, price-to-book of 1.49, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $1.83 and $30.80, and currently trades 88.3% below its 52-week high.

On profitability, NCEL generates a return on equity (ROE) of -200.00%, return on capital employed of -400.00%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides